Patent AnalyticsExaminers
Rankings

Company or institution

AVENTIS PHARMA S.A.

106 applicationsfiled 2006 to 2019

Allowance rate
53%
−23 pts vs the USPTO range 43% to 62%
Rejections before allowance
1.7
level with the USPTO
Months to first action
12.7 mo
−5.9 vs the USPTO
Needed an RCE
19%
−8 pts vs the USPTO

Timeline

Applications by filing year: drag across the years to study a period

Allowed in green, abandoned in red, pending in grey. The figures above and the charts that can be recomputed by filing year follow the span you pick.

Compared with the office

Against every applicant before the USPTO

Unlock the comparison with the officeFree with an account. No card needed.

Create a free account

Trend

Allowance by filing year

Unlock the trendIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Domains

Where the applications fall

CPC subclasses

C07D Heterocyclic compounds46 apps
A61K Medical preparations39 apps
C12N Microorganisms or enzymes6 apps
C08B 3 apps
G01N Investigating or analysing materials3 apps
A61M Devices for introducing media into the body2 apps

Art units

162614 apps
162413 apps
16299 apps
16256 apps
16276 apps
16215 apps

Who represents them

Law firms and agents on their applications

Bars show the share of decided applications that were allowed.

Unlock the firms on their applicationsIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Rejection fingerprint

What gets rejected, by statute

Share of parsed office actions raising each ground; blue is the USPTO.

Unlock the rejection fingerprintIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

What works

Allowance by strategy used

Unlock what works for this filerIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Interviews

Does an interview help?

Unlock the interview figuresFree with an account. No card needed.

Create a free account

Applications

Every application in the record

ApplicationTitleFiledStatusRejectionsRCEsTo 1st action
16272315ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN2019-02-11Abandoned205.6 mo
16251143NOVEL ANTITUMORAL USE OF CABAZITAXEL2019-01-18Abandoned201.3 mo
16188687CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME2018-11-13Abandoned0011.6 mo
15127122Method and apparatus for adaptive signal processing2012-01-10Allowed1012.0 mo
15181401Composition and method for controlled release2015-02-11Abandoned4123.0 mo
15387627Distributed ledger transaction verification2018-03-12Allowed3020.0 mo
15894558Thermal management of battery assemblies2021-04-13Pending2117.0 mo
15342907Machine learning model for anomaly detection2012-05-14Allowed1014.0 mo
15416032Wireless power transfer coil arrangement2015-06-15Abandoned4125.0 mo
15777617Catalyst for selective hydrogenation2018-07-16Allowed3022.0 mo
Unlock all 106 applications, each with its full timelineIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in